Bristol Myers Squibb™

RUTGERS
Institute for Pharmaceutical Industry Fellowships

PHARMACEUTICAL INDUSTRY

PHYSICIAN FELLOWSHIP PROGRAM

Scan or click here to apply

2024
2025

TABLE OF CONTENTS

What is Pharmaceutical Medicine? 3

About Bristol Myers Squibb 4

Program Description and Benefits 8

Rotational Responsibilities 9

What Past Fellows Have to Say, and Current Fellows 11

Program Governance 13

Rutgers Institute for Pharmaceutical Industry Fellowships 14

Requirements and Application Process 16

FELLOWSHIP CAMPUS LOCATIONS:

PRINCETON PIKE (PPK)

Lawrenceville, NJ
(Main Campus)

GIRALDA FARMS

Madison, NJ

WHAT IS PHARMACEUTICAL MEDICINE?

PHYSICIANS IN THE PHARMACEUTICAL INDUSTRY:

Evaluate medicines

Ensure patient safety

Analyze risks and benefits

Review medical information

Advance public health

CAREER OPPORTUNITIES

Clinical Development

Drug Safety

Medical Affairs

Pharmaceutical physicians play a vital role across all stages of the drug development process, utilizing their specialized knowledge to **progress innovative medicines and ensure the safety, efficacy, and appropriate use of medicines for patients.**

Worldwide, the current drug development pipeline is comprised of **thousands of new medicines**. Skilled physicians with expertise in pharmaceutical medicine leverage their clinical aptitude and scientific knowledge to drive these advancements, with the goal of **enhancing patient well-being** and translating science to **patient care**.

ABOUT BRISTOL MYERS SQUIBB

OUR MISSION

To discover, develop, and deliver innovative medicines that help patients prevail over serious diseases

OUR VISION

To be the world's leading biopharma company that transforms patients' lives through science

OUR VALUES

INTEGRITY | INNOVATION | URGENCY
PASSION | ACCOUNTABILITY | INCLUSION

Bristol Myers Squibb™

ABOUT BRISTOL MYERS SQUIBB

FIRST-IN-CLASS PIPELINE

50+ investigational therapies

Cutting-edge technologies & discovery platforms

- Cell & gene therapy
- Protein homeostasis
- Biologics
- Small molecules
- Chemistry

Therapeutic areas with unmet needs

- Oncology
- Hematology
- Cardiovascular
- Immunology
- Fibrotic diseases
- Neuroscience

Patient-centric innovation through in-house research and external collaboration

MANUFACTURING COMPLEX THERAPIES AROUND THE WORLD AND DELIVERING THEM TO PATIENTS

~10,600 employees, working in **19** manufacturing and development sites globally

Bringing medicines to 85 global regions

Making 40 marketed products for patients

Producing 85 different assets in development

ABOUT BRISTOL MYERS SQUIBB

OUR INNOVATIVE PIPELINE

Bristol Myers Squibb focuses on discovering and developing innovative medicines that address serious diseases in areas of significant unmet medical need. We concentrate our research efforts in the following core therapeutic areas: Oncology, Hematology, Cardiovascular, Immunology, and Neuroscience.

Scan or click here to learn more

Active Clinical Development Portfolio

	Phase I				Phase II		Phase III	Life Cycle Management
Oncology	AHR Antagonist*	AR LDD	MAGEA4/8 TCER*	TGFβ Inhibitor	Anti-IL-8	Anti-TIGIT	Subcutaneous nivolumab	Opdivo (nivolumab), Opdualag (nivolumab/relatlimab), Yervoy (ipilimumab)
	Anti-CCR8	Claudin18.2 ADC	NME 1	TIGIT Bispecific	Anti-CTLA-4 NF-Probody® Therapeutic	BET Inhibitor[1] (CC-90010)	Subcutaneous nivolumab + relatlimab	
	Anti-ILT4	DGK Inhibitor	NME 2		Anti-Fucosyl GM1	farletuzumab ecteribulin		
	Anti-NKG2A	JNK Inhibitor	SHP2 Inhibitor		repotrectinib			
Hematology	alnuctamab	CD33 NKE	GPRC5D CAR T		BET Inhibitor (BMS-986158)	golcadomide (CC-99282)	iberdomide	Abecma, Idhifa, Onureg, Breyanzi, Inrebic, Reblozyl, Empliciti, Istodax, Revlimid
	Anti-SIRPα	CD47xCD20	GSPT1 CELMoD (CC-90009)				mezigdomide (CC-92480)	
	BCMA NKE	CK1α CELMoD						
Cardiovascular	FXIα Inhibitor				Cardiac Myosin Inhib. (MYK-224)	danicamtiv	milvexian (FXIa Inhibitor)	Camzyos, Eliquis
Immunology	Anti-CD40	IL2-CD25	RIPK1 Inhibitor		afimetoran (TLR 7/8 Inhib.)	LPA1 Antagonist	cendakimab	Nulojix, Orencia, Sotyktu, Zeposia
	CD19 NEX T	PKCθ Inhibitor			HSP47	TYK2 Inhibitor (BMS-986322)		
Neuroscience	Anti-MTBR-Tau	BTK Inhibitor	eIF2b Activator	FAAH/MGLL Dual Inhibitor				

1 - In development for Immunology and Neuroscience
* Partner-run study

Bristol Myers Squibb™

ABOUT BRISTOL MYERS SQUIBB

PEOPLE AND BUSINESS RESOURCES

Driving business results in:

- Talent management
- STEM education
- Business insights
- Diversity in clinical trials
- Corporate reputation
- Community responsibility

Scan or click here to learn more

VCN Veterans Community Network

OLA Organization for Latino Achivement

CLIMB Cultivating Leadership and Innovation for Millenials and Beyond

PAN Pan Asian Network

BOLD Black Organization for Leadership and Development

DAWN Disability Advancement Workplace Network

PRIDE Alliance

B-NOW Bristol Myers Squibb Network of Women

PROGRAM DESCRIPTION AND BENEFITS

PROGRAM DESCRIPTION

BMS will be recruiting **2 Physician Fellows** for the **2024-2025** program

A one-year training program in collaboration with the **Rutgers Institute for Pharmaceutical Industry Fellowships.**

Consists of two 6-month rotations in 2 of the following functions:

- **Clinical Development**
- **US Medical Affairs**
- **Worldwide Patient Safety**
- **Worldwide Medical Affairs**

**Rotations are assigned by the Physician Fellowship Steering Committee and are determined by balancing applicant interests and available opportunities.*

In addition to participation as a contributing team member at BMS, fellows will benefit from **monthly professional development sessions** hosted by the Rutgers Institute for Pharmaceutical Industry Fellowships.

BENEFITS

Special credential designation upon completion of the program, **Rutgers University Certified Industry Fellow (RUCIF)**

- **Key insights** and training to **facilitate transition from clinical practice** and lead a successful career in biopharmaceuticals
- **Exposure** to the drug development process, including clinical trial planning and execution, safety monitoring, and medical strategy globally and across major markets
- **Mentorship** by industry leaders across clinical trial research, epidemiology, health economics and outcomes research, and medical strategy
- **Participation** in clinical conferences and other training opportunities



Bristol Myers Squibb™

6-MONTH ROTATIONAL RESPONSIBILITIES

CLINICAL DEVELOPMENT

Clinical Development is responsible for the architecture of clinical trial concepts, protocol development, study startup, study execution, data cleaning, clinical interpretation of data, publication contributions, and are a clinical resource for regulatory filings and queries

- Align clinical development strategy with Development Team Leadership
- Develop innovative trial design options within a designated asset team with expectations to support global regulatory filings
- Partner cross-functionally with early- or late-stage Clinical Development, Medical, & Commercial teams
- Serve as resource for investigators on patient eligibility, safety, and protocol questions

US MEDICAL AFFAIRS

US Medical Affairs plays a critical role in forging broadly aligned medical strategies, translating them into tactical plans, and leading the execution of these plans

- Collaborate with Global Drug Development (GDD) and Worldwide Medical Affairs in the development of long-term strategies that include understanding emerging trends and anticipating future obstacles, risks, and business opportunities
- Identify data gaps, develop strategies for US non-registrational data generation, and drive US investigator sponsored research
- Partner with US Commercial & Access organizations to integrate medical perspectives into commercialization processes and ensure appropriate alignment between medical and commercial teams

6-MONTH ROTATIONAL RESPONSIBILITIES

WORLDWIDE PATIENT SAFETY

Worldwide Patient Safety (WWPS) is responsible for providing strategic oversight and delivery of medical safety assessments to enable development and optimal use of BMS medicines through innovative pharmacovigilance and risk management

- Participate in support management team (SMT) and safety data review (SDR) meetings
- Detect and assess signals and support any resultant activities, such as revisions to core safety information
- Drive risk management activities, including risk strategies for assets in all phases of development and life cycle
- Review and provide direction for strategic decisions guiding aggregate and ad hoc safety report content
- Participate in WWPS process improvement projects

WORLDWIDE MEDICAL AFFAIRS

Worldwide Medical Affairs is responsible for launch planning, launch readiness coordination, strategic planning, and review of key publications and content resources

- Plan and manage logistics and content development for advisory boards, Thought Leader encounters, and symposia
- Review key medical insights and disseminate them to the core team
- Provide strategy-driven feedback on investigator-led research proposals
- Provide strategic input on clinical development plans and trial planning
- Align strategically with Health Economics and Outcomes Research for dossier and key data deliverables to support market access

WHAT PAST FELLOWS HAVE TO SAY

ALEEF RAHMAN, MD, MPH, MBA, MSc, RUCIF

Clinical Development & Worldwide Patient Safety Fellow | 2022-2023

"The Bristol Myers Squibb Physician Fellowship program was a transformative and enriching experience that provided a stimulating and supportive environment for my professional development within the pharmaceutical industry. The unparalleled mentorship and collaboration during my time in the Oncology Global Drug Development & Worldwide Patient Safety organizations empowered me to tackle the complexities of the drug development process. I am truly grateful for the opportunities provided by this fellowship, as they have undoubtedly shaped me into a more competent and skilled pharmaceutical physician. Bristol Myers Squibb's commitment to advancing medical knowledge through this fellowship is commendable, and I enthusiastically recommend it to any aspiring physician seeking an exceptional training experience within the industry."

MICHAEL PLEWINSKI, MD, PharmD, RUCIF

US Medical Affairs & Worldwide Medical Affairs Fellow | 2022-2023

"The BMS Physician fellowship program was an exceptional introduction to the emerging field of pharmaceutical medicine in the United States, which offers physicians an opportunity to leverage their highly specialized skills in innovative and impactful ways in the pharmaceutical industry. My work throughout the physician fellowship program at BMS encompassed several therapeutic areas within Oncology and Hematology Medical Affairs, providing a comprehensive and engaging experience which serves as the foundation for my career growth and trajectory. I would highly recommend the program for any physician interested in clinical research, the pharmaceutical industry, or looking to explore non-clinical career paths."

ENIOLA YEATES, MD, PhD, RUCIF

US Medical Affairs & Clinical Development Fellow | 2021-2022

"The Physician Fellowship at BMS is a great introduction into the world of the pharmaceutical industry. My fellowship year, split between clinical development and medical affairs, allowed me to gain an understanding of the role of a physician in both functional areas and find my niche in the broader matrix team. I was able to gain the fundamental skills to transition into the role of Associate Clinical Trial Physician at BMS. I recommend this fellowship for physicians hoping to ease their transition into the pharmaceutical industry with a support system of passionate mentors and peers."

LOLA ALAKIJA, MD, RUCIF

Worldwide Medical Affairs & Worldwide Patient Safety Fellow | 2021-2022

"The BMS Physician Fellowship program provided a valuable opportunity to gain a comprehensive understanding of the pharmaceutical industry and drug development process. During my time in Worldwide Medical Affairs and Worldwide Patient Safety, I had the privilege of working with dedicated preceptors who were committed to my professional growth. They provided numerous opportunities for collaboration, leadership, and participation in cross-functional activities. These experiences laid a solid foundation for a career in the pharmaceutical industry. I highly recommend this program as an exceptional opportunity for physicians seeking a seamless transition into the pharmaceutical industry."

WHAT PAST FELLOWS HAVE TO SAY

"I had a terrific experience during my fellowship year which was focused on Medical Affairs and Clinical Development. It was really exhilarating and highly motivating to work in an environment where everyone is so dedicated and passionate and to learn about drug development with the support of great preceptors, mentors, and co-fellows. I would highly encourage those interested in an alternative career path and with an interest in industry to apply for this well-tailored and rewarding opportunity."

— HINA KHAN, MD
US Medical Affairs & Clinical Development Fellow | 2019-2020

"During my fellowship at BMS within US Medical Affairs and Clinical Development, I have actively participated in drug launch activities, review of investigator-sponsored trial proposals, protocol writing and monitoring of industry-sponsored trials, and data analysis. This is a hands-on experience offering broad exposure to the pharmaceutical industry, supportive mentorship and networking opportunities. I highly recommend it to anyone interested in learning more about the industry or considering a career in pharma."

— AARON CINER, MD
US Medical Affairs & Clinical Development Fellow | 2020-2021

"The most refreshing part of the Rutgers Pharmaceutical Industry Fellowships program was the willingness of my preceptors and colleagues to teach me about industry. Even since completing fellowship, I recognize in my peers a genuine enthusiasm for bringing medicines to market and making Bristol Myers Squibb the best company in the industry."

— GRACE CROCKET, MD
US Medical Affairs Fellow | 2018-2019

CURRENT FELLOWS

MAHA SYED, MD
Clinical Development & Worldwide Medical Affairs Fellow | 2023-2024

ATIF ASAD SIDDIQUI, MD, MS
US Medical Affairs & Worldwide Patient Safety Fellow | 2023-2024

POST-DOCTORAL PROGRAM GOVERNANCE

EXECUTIVE SPONSORS

NICHOLAS BOTWOOD, BSc, MB BS, MFPM, FRCP
Senior Vice President
Worldwide Medical Oncology

DANIEL QUIRK, MD, MPH, MBA
Senior Vice President
US Medical

STEERING COMMITTEE

TRIXIA CAMACHO, PharmD
Executive Director
Clinical Development Team Lead
Opdivo/Yervoy

GARY ZUCKERMAN, MD
Therapeutic Area Lead
Opdivo/Yervoy LCM
Worldwide Patient Safety

JENINE SANZARI, PhD
Senior Director
Medical Strategy and Portfolio
Operational Excellence

KIM TRAN, PharmD
Executive Director
US Field Medical
Hematology

PRECEPTORS

DHIREN PATEL, MD, MBA
Senior Clinical Trial Physician
Relatlimab
Oncology Clinical Development

JAMES WHITE, PharmD, MS
Executive Director
US Medical Oncology
Lung, Emerging Tumors, & Abraxane

ANILA QURESHI, MD, MPH
Senior Clinical Trial Physician
Oncology Clinical Development

Physician Fellowship Training Opportunities in the Pharmaceutical Industry

Rutgers Pharmaceutical Industry Fellowship Program

Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey

Joseph A. Barone, Pharm.D., F.C.C.P.
Dean and Professor II
Ernest Mario School of Pharmacy, Rutgers University

Carolyn Seyss, Pharm.D., RUCIF
Fellowship Director
Institute for Pharmaceutical Industry Fellowships, Ernest Mario School of Pharmacy

Michael Toscani, Pharm.D.
Research Professor
Fellowship Director Emeritus
Institute for Pharmaceutical Industry Fellowships

PROGRAM HISTORY

In 1984, at Rutgers, The State University of New Jersey, the Ernest Mario School of Pharmacy and two pharmaceutical companies began a first-of-its-kind collaborative pilot program to evaluate the potential contributions of clinically-trained pharmacists within a pharmaceutical industry practice setting. Following the successful pilot, the Rutgers Pharmaceutical Industry Fellowship (RPIF) Program grew significantly and expanded to include 27 companies within the pharmaceutical and biopharmaceutical industry and approximately 350 Fellows.

In 2002, Dr. Ernest Mario generously provided an endowment to establish the **Institute for Pharmaceutical Industry Fellowships** to enhance and promote the role of pharmacists in industry through the RPIF Program. The Institute staff members:

- provide leadership and administrative support
- promote quality, communication, scholarly activity, and professional development
- arrange specialized Fellowship training opportunities within the pharmaceutical and biopharmaceutical industry.

In 2018, our Program leveraged this successful track record to expand, offering interdisciplinary Fellows' training by adding select physician Fellowship opportunities to our well-established training program.

The RPIF Program has thrived under the leadership of the founder, Dr. Joseph A. Barone, Dean and Professor II of the Ernest Mario School of Pharmacy, Dr. Carolyn Seyss, the Director for the Institute for Pharmaceutical Industry Fellowships, and Dr. Michael Toscani as the Director Emeritus.

The RPIF Program Certificate is now associated with special credentials so our alumni can now proudly identify themselves as **RUCIF (Rutgers University Certified Industry Fellow).** Well over 1,500 Post-Doctoral Fellows have completed the RPIF Program, most of whom are experiencing influential and rewarding careers in the pharmaceutical and biopharmaceutical industry throughout the US and abroad. The RPIF Program has Preceptors and Mentors from industry who share their knowledge and experiences with the Fellows through an intense but closely-guided training program. Assignments and projects are challenging, meaningful, and designed to enhance understanding of the pharmaceutical and biopharmaceutical industry and the Fellow's functional area(s). Our goal is to provide the environment for Fellows to build the foundations to fuel their careers as future leaders in the industry.

Connect with us on social media : @RutgersFellow

RUTGERS
Institute for Pharmaceutical Industry Fellowships

Professional Development Series

All Fellows gather once monthly as a group to participate in the Professional Development Day (PDD) series, an important component of their training that complements the hands-on experience provided at the partner companies. The PDDs are steered by a committee of Fellows and are designed to enhance the Fellows' leadership skills such as emotional intelligence, communication, critical decision making, and presentation skills. Fellows develop skill sets under the guidance of external trainers and accomplished RPIF alumni. PDDs also provide general knowledge about various aspects of drug development/commercialization and issues facing the pharmaceutical and biopharmaceutical industry, and promote connectivity and a sense of community among Fellows and alumni from different companies and disciplines.

The Fellows can learn from each other through individual and group presentations on topics and issues related to the pharmaceutical and biopharmaceutical industry. The dynamic forum of PDD provides an opportunity for open discussion and debate among Fellows, Rutgers faculty, and company Preceptors. In addition, outside experts provide training and professional development in a variety of areas (e.g., tools for corporate success, professional writing, presentations, meeting facilitation, negotiating, influencing, networking, conflict resolution, giving and receiving feedback, and business etiquette). Other PDD guest speakers include senior industry executives, including our successful RPIF Program alumni, who share their career paths, insights, and experiences. Importantly, PDDs provide an excellent opportunity for Fellows to interact with each other and develop lasting personal friendships and a strong professional network of Fellows, faculty, alumni, and other industry executives.

Key Program Features

The Rutgers Pharmaceutical Industry Fellowship Program **FOSTER**s the growth and development of future pharmaceutical and biopharmaceutical industry professionals and leaders through key program features:

F	**Family of Leading Companies** – Partners include several of the top global pharmaceutical and biopharmaceutical companies and offer large to small company environments.
O	**Outstanding Alumni Track Record** – Well over 1,500 alumni hold prominent positions at many leading companies, including VP and C-suite levels.
S	**Strong Network** — Fellows develop valuable, lasting connections with each other, alumni, Preceptors, and Rutgers EMSOP faculty.
T	**Trusted and Proven Since 1984**—the Rutgers Fellowship Program is nationally recognized, trusted, and proven as the key pathway to industry for pharmacists as future leaders.
E	**Enhanced Career Development** – Breadth of experiences informs career path choices, increasingly challenging assignments build depth of experience, and visibility creates opportunities - enhancing the potential for accelerated career paths.
R	**Rigorous Academic Component** – Rutgers affiliation provides academic and professional development opportunities, and adjunct faculty appointments at EMSOP.

Rutgers, The State University of New Jersey, with over 67,000 students in its three campuses, is one of the major state university systems in the United States. The New Jersey College of Pharmacy was founded in 1892 and was incorporated into the University in 1927. The **Ernest Mario School of Pharmacy (EMSOP)** is part of Rutgers Biomedical and Health Sciences (RBHS). The Rutgers EMSOP is located on the University's main science and technology campus in Piscataway, New Jersey. Because of its relationship with and close proximity to most of the nation's leading pharmaceutical and biopharmaceutical companies, the EMSOP and the RPIF Program are uniquely capable of providing Fellows with advanced training in the pharmaceutical and biopharmaceutical industry.

Connect with us on social media : @RutgersFellow

RUTGERS
Institute for Pharmaceutical Industry Fellowships

Application Process and Eligibility Requirements:

Physician Fellows for the Rutgers Pharmaceutical Industry Fellowship Program are selected on a nationally competitive basis. Candidates must have an M.D. or D.O., with clinical experience such as completed residencies or fellowships preferred.

How to Apply:

The RPIF Program is highly competitive. Candidates will be selected for interviews on a rolling basis, so we strongly encourage you to submit your application as soon as possible.

Interested candidates may submit their application with short-answer questions and supporting materials (letter of intent, curriculum vitae, and 3 letters of recommendation) as soon as October 6, 2023 by visiting our website at:
https://pharmafellows.rutgers.edu/physicians/how-to-apply/

All application materials **must be submitted electronically to the RPIF Website** per instructions on the site.

Your Letter of Intent & Letters of Recommendation should be addressed to:

Joseph A. Barone, Pharm.D., F.C.C.P.
Dean and Professor II
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
160 Frelinghuysen Road
Piscataway, NJ 08854-8020

Required Items	Submit By
Application with short-answer questions	October 13th
Letter of Intent (LOI)	October 13th
Curriculum Vitae (CV)	October 13th
Letters of Recommendation (LORs)	December 1st

Connect with us on social media : @RutgersFellow

RUTGERS Institute for Pharmaceutical Industry Fellowships